The Role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in Diabetes-Related Neurodegenerative Diseases.
The Role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in Diabetes-Related Neurodegenerative Diseases.
复制标题
胰高血糖素样肽 1 受体激动剂 (GLP-1 RA) 在糖尿病相关神经退行性疾病中的作用
DOI：
10.2147/dddt.s348055
复制
发表时间：
2022
期刊：
影响因子：
--
通讯作者：
Wang G
中科院分区：
文献类型：
--
作者：
Cheng D;Yang S;Zhao X;Wang G
摘要 最近的临床指南强调了老年糖尿病患者认知障碍筛查的重要性，然而，人们对药物治疗仍缺乏了解。胰高血糖素样肽 1 受体激动剂 (GLP-1 RA) 广泛用于治疗 2 型糖尿病，潜在应用可能包括治疗肥胖以及与胰岛素联合辅助治疗 1 型糖尿病。越来越多的证据表明，GLP-1 RA 具有治疗神经退行性疾病的潜力，特别是与糖尿病相关的阿尔茨海默病 (AD) 和帕金森病 (PD)。在这里，我们回顾了 GLP-1 RA 在糖尿病相关退行性疾病（包括 AD 和 PD）中神经保护作用的分子机制及其潜在作用。
Abstract Recent clinical guidelines have emphasized the importance of screening for cognitive impairment in older adults with diabetes, however, there is still a lack of understanding about the drug therapy. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are widely used in the treatment of type 2 diabetes and potential applications may include the treatment of obesity as well as the adjunctive treatment of type 1 diabetes mellitus in combination with insulin. Growing evidence suggests that GLP-1 RA has the potential to treat neurodegenerative diseases, particularly in diabetes-related Alzheimer’s disease (AD) and Parkinson’s disease (PD). Here, we review the molecular mechanisms of the neuroprotective effects of GLP-1 RA in diabetes-related degenerative diseases, including AD and PD, and their potential effects.